The Risk Of Infection And Related Factors In Patients With Crohn's Disease Treated With Infliximab

Objective:Crohn's disease(CD)is a non-specific and immune-related disease,and its cause remains unknow.In recent years,the incidence of crohn's disease has been increasing in China.Currently,the first-line treatment is biological agents,and Infliximab(IFX)is the most widely used biological agent.However,because biological agents can suppress the patient's immune system,patients with crohn's disease who take IFX are at increased risk of infection.The aim of this study is to explore the types,characteristics and related risk factors of infection after infliximab treatment in patients with CD.Methods:The patients with CD underwent the IFX from July 2010 to April 2019 were collected from the clinical medical HIS database of affiliated hospital of nanjing university of traditional Chinese medicine.The types and characteristics of infection were counted and risk factors related to infection were analyzed.Results:A total of 207 patients with CD were included in this study.36%of the patients developed infection after IFX application,15%were opportunistic infection,21%were adverse infection events,and no serious infection occurred.Univariate analysis showed that gender,the time from the onset of initial symptoms to the diagnosis of CD,and the level of RBC,HB,albumin and CRP were all correlated with infection after IFX treatment in CD patients(all P<0.05).Multivariate logistic regression analysis showed that male[OR=0.357,95%CI(0.187,0.682),P=0.002]was a protective factor for infection.Higher CRP levels[OR=1.02,95%CI(1.006,1.034),P=0.004]are risk factors for infection.Conclusion:Patients with CD had a higher risk of infection after IFX application.Men are protective factors for infection,while longer delays in diagnosis,poorer nutrition and the worse severity of the inflammation are risk factors for infection.Therefore,in clinical practice,infection screening around the use of IFX should be strengthened in patients with CD.